Back to results
US 2026/0042843 A1Published application
Methods for treating endometrial and ovarian hyperproliferative disorders
AssigneeTemple Therapeutics, Inc.
InventorGhassan SAED
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTemple Therapeutics, Inc.
InventorGhassan SAED
Estimating the term…
The disclosure provides for methods and compositions that target the interaction of αV/β1 integrin and monomeric MPO in ovarian cancer and other hyperproliferative disorders. Accordingly, aspects of the disclosure relate to a method for treating endometrial or ovarian hyperproliferative disorders in a subject, the method comprising administration of an inhibitor of αV/β1 integrin, an MPO inhibitor, and/or the combination of an αV/β1 integrin and an MPO inhibitor to the subject. In some aspects, the hyperproliferative disorder comprises ovarian cancer or epithelial ovarian cancer. In some aspects, the hyperproliferative disorder comprises endometriosis.
A method for treating endometrial or ovarian hyperproliferative disorders in a subject, the method comprising administration of an inhibitor of αV/β1 integrin, an MPO inhibitor, and/or the combination of an αV/β1 integrin and an MPO inhibitor to the subject.
A method for evaluating a subject comprising detecting αV/β1 integrin in a biological sample from the subject.
A method for making a complex comprising contacting a biological sample with an antibody that binds to αV/β1 integrin.
A method for treating a subject with an endometrial or ovarian hyperproliferative disorder, the method comprising administering an treatment for the endometrial or ovarian hyperproliferative disorder to a subject that has had the level of αV/β1 integrin evaluated in a biological sample from the subject.
A method of diagnosing or prognosing a subject with an endometrial or ovarian hyperproliferative disorder comprising
A method for monitoring a subject being treated for an endometrial or ovarian hyperproliferative disorder with a therapeutic agent, the method comprising
A kit comprising one or more anti-αV/β1 integrin, anti-αV integrin, and/or anti-β1 integrin antibodies or antigen binding fragments thereof.
Dependencies are inferred from the claim text.